UP!

News

Cara Therapeutics, Inc. 3.12% (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-03-09 Future report Set alerts
Q3 2020 2020-11-06 Future report Set alerts
Q2 2020 2020-08-10 -0.54 -0.54
Q1 2020 2020-05-11 -0.62 -0.62
Q4 2019 2020-02-27 -0.61 -0.61
Q3 2019 2019-11-05 -0.74 -0.74
Q2 2019 2019-08-07 -0.58 -0.58
Q1 2019 2019-05-07 -0.56 -0.56
Q4 2018 2019-03-12 -0.52 -0.52
Q3 2018 2018-11-06 -0.51 -0.51

Ratings

2016-05-06 Reiterated Rating Needham & Company LLC Buy
2016-05-06 Reiterated Rating Canaccord Genuity Buy $30.00
2016-04-23 Reiterated Rating Piper Jaffray Overweight $23.00
2016-04-23 Reiterated Rating Piper Jaffray Cos. Overweight $23.00
2016-04-21 Reiterated Rating Needham & Company LLC Buy
2016-04-20 Reiterated Rating Cantor Fitzgerald Buy
2016-03-12 Reiterated Rating Janney Montgomery Scott Buy $23.00 to $18.00
2016-03-11 Reiterated Rating Cantor Fitzgerald Buy $28.00
2016-03-11 Initiated Coverage Needham & Company LLC Buy $27.00
2016-02-29 Lower Price Target Laidlaw Buy $30.00 to $17.00
2016-02-28 Reiterated Rating Cantor Fitzgerald Buy $28.00
2016-02-28 Reiterated Rating Needham & Company LLC Buy $27.00
2016-02-26 Reiterated Rating Piper Jaffray Overweight $23.00
2015-12-31 Reiterated Rating Piper Jaffray Top Pick to Top Pick $34.00
2015-12-11 Initiated Coverage Cantor Fitzgerald Buy $28.00
2015-12-09 Reiterated Rating Needham & Company LLC Buy $27.00
2015-12-09 Reiterated Rating Piper Jaffray Buy $34.00
2015-11-11 Reiterated Rating Needham & Company LLC Buy $27.00
2015-11-11 Reiterated Rating Canaccord Genuity Buy $30.00
2015-11-04 Initiated Coverage Janney Montgomery Scott Buy $28.00
2015-11-03 Initiated Coverage Cantor Fitzgerald Buy $28.00
2015-08-12 Reiterated Rating Canaccord Genuity Buy $30.00
2015-08-11 Initiated Coverage Needham & Company LLC Buy $27.00
2015-07-24 Boost Price Target Canaccord Genuity Buy $20.00 to $30.00
2015-07-24 Reiterated Rating Piper Jaffray Buy $30.00 to $34.00
2015-07-23 Reiterated Rating Needham & Company LLC Buy $22.00 to $27.00
2015-07-23 Boost Price Target Janney Montgomery Scott Fair Value $27.00
2015-06-24 Set Price Target Piper Jaffray Buy $30.00
2015-06-24 Set Price Target Needham & Company LLC Buy $22.00
2015-05-14 Reiterated Rating Canaccord Genuity Buy $20.00
2015-05-13 Initiated Coverage Needham & Company LLC Buy $22.00
2015-03-27 Reiterated Rating Canaccord Genuity Buy $20.00
2015-03-27 Reiterated Rating Needham & Company LLC Buy $22.00
2015-03-03 Initiated Coverage MLV & Co. Buy $26.00
2015-01-09 Initiated Coverage Canaccord Genuity Buy $20.00
2014-12-09 Initiated Summer Street Research Buy $20
2014-12-09 Initiated Coverage Summer Street Buy $20.00
2014-05-15 Boost Price Target Canaccord Genuity $25.00 to $29.00
2014-02-27 Initiated Needham Buy $27
2014-02-27 Initiated Coverage Needham & Company LLC Buy $27.00
2014-02-25 Initiated Coverage Canaccord Genuity Buy to Buy $25.00
2014-02-25 Initiated Coverage Stifel Nicolaus Buy $21.00
2014-02-25 Initiated Coverage Janney Montgomery Scott Buy
2014-02-25 Initiated Coverage Piper Jaffray Overweight $23.00
2016-05-06 Reiterated Rating Needham & Company LLC Buy
2016-05-06 Reiterated Rating Canaccord Genuity Buy $30.00
2016-04-23 Reiterated Rating Piper Jaffray Overweight $23.00
2016-04-23 Reiterated Rating Piper Jaffray Cos. Overweight $23.00
2016-04-21 Reiterated Rating Needham & Company LLC Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
RHO Ventures VI LP 15.76%  (3568057) CARA /
VOGELBAUM MARTIN 13.55%  (3068057) CARA / NRX /
Moller Charles Ph.D. 6.96%  (1576404) CARA /
CHALMERS DEREK T President & CEO 4.73%  (1071392) CARA /
Slagel Dean 4.70%  (1064338) CARA /
Lewis Michael E Chief Scientific Advisor 1.39%  (314988) CARA /
Menzaghi Frederique Ph.D. VP-Research & Development 0.53%  (119000) CARA /
Schoell Josef Chief Financial Officer 0.22%  (50000) CARA /
ALTA BIOPHARMA PARTNERS III LP 0.19%  (43212) AEGR / CARA / CMRX / MGNX / SNSS /
Stauffer Joseph William Chief Medical Officer 0.06%  (13442) CARA / DRRX /

Comments